For the vast majority of patients, tuberculosis (TB) diagnosis still depends primarily on sputum smear microscopy, with chest radiography and tuberculin skin tests being available in some settings. These tests have limitations in sensitivity and specificity, especially in people living with HIV[@ref1]--[@ref3]. Mycobacterial cultures on solid media may take weeks to become positive. Improved diagnostic tests, such as liquid culture of *Mycobacterium tuberculosis* (*M. tuberculosis*) and nucleic acid amplification tests are often too expensive and complex to be used in routine by TB control programmes in low-income settings. The Xpert® MTB/RIF assay (Cepheid Inc, Sunnyvale, USA), a major advance in TB diagnostics that was recently endorsed by the World Health Organization (WHO), provides high sensitivity for detection of TB and rifampicin resistance; however, high cost is a barrier for scaling-up this new technology in many areas where the epidemic is most severe[@ref4].

Serological tests have a long history and have been used successfully for the diagnosis of many infectious diseases (*e.g*., HIV, syphilis, and viral hepatitis). In this review, serological tests refer to tests that detect humoral immune responses (antibodies) to *M. tuberculosis* antigens. In comparison to microscopy, serological TB tests could potentially enable rapid diagnosis as these tests have the advantages of speed (results can be available within hours or minutes), technological simplicity, and modest training requirements. In addition, these tests could be adapted to point-of-care formats and performed at peripheral health facilities without onsite microscopy services.

Although currently, the International Standards for TB Care discourage the use of serological tests in routine practice[@ref5] and no international guidelines recommend their use, dozens of commercial serological tests for TB diagnosis are offered for sale in many parts of the world[@ref6]. According to a recent survey, serological tests are widely used in high-burden countries, including Afghanistan, Bangladesh, Brazil, Cambodia, China, India, Kenya, Myanmar, Nigeria, Pakistan, Russia, South Africa, Thailand and Vietnam[@ref7]. India alone has a market for TB serological tests that exceeds the market for conventional microbiological tests (*e.g*., smears and culture). An estimated 1.5 million TB serological (ELISA) tests are performed in India every year[@ref7][@ref8]. The majority of these tests are performed by the private sector, the primary source of care for a large percentage of TB patients in India. The test kits, which are usually imported, account for an expenditure conservatively estimated at US \$ 15 million (![](IJMR-135-695-g001.jpg) 825 million)[@ref7] per year. Claims of high accuracy in package inserts are common ([Table I](#T1){ref-type="table"}). Recent media reports have highlighted the potential for TB misdiagnosis using serological tests and the fact that these tests are not used in developed countries, but instead marketed in resource-constrained countries with weak regulatory systems[@ref8]--[@ref10].

###### 

Selected serological assays for tuberculosis on the Indian market
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Serological tests for TB diagnosis, review {#sec2-1}
==========================================

This article reviews the evidence on the diagnostic accuracy of serological tests for the diagnosis of active TB (pulmonary and extra-pulmonary TB). The evidence is derived largely from systematic reviews using standard guidelines and methods appropriate for diagnostic test accuracy reviews ([Table II](#T2){ref-type="table"})[@ref11][@ref12]. An expanding evidence base continues to document concerns about serological tests. In addition to the survey of high burden countries mentioned above[@ref7], we present key findings from two studies with particular relevance to India: a cost-effectiveness analysis of TB serological testing in India[@ref13] and a root-cause analysis of why serological testing is used widely by private Indian providers[@ref14]. Finally, we discuss the translation of evidence into policy and the way forward for India.

###### 

Systematic reviews on the performance of commercial serological tests for the diagnosis of active tuberculosis
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Systematic reviews of serological TB tests {#sec2-2}
==========================================

The performance of serological tests was evaluated in a comprehensive review of rapid TB diagnostics[@ref15]. Studies with a cohort or case series type design were eligible for inclusion. The reference standards were culture and clinical diagnosis. For pulmonary TB (8 test evaluations), commercial serological tests showed modest performance \[diagnostic odds ratio (DOR) = 7.30 (95% CI 1.95, 27.24)\] with a pooled sensitivity of 88 per cent and pooled specificity of 50 per cent. When only studies meeting at least two methodological quality criteria (*e.g*., representative patient population and blinding of the serological test result) were considered (7 evaluations), the DOR decreased to 6.35 (95% CI 0.59, 67.98) and the sensitivity decreased to 34 per cent. For extra-pulmonary TB (4 test evaluations) pooled sensitivity was less than 50 per cent and pooled specificity was 93 per cent.

Three systematic reviews were commissioned by the WHO Special Programme for Research and Training in Tropical Diseases (TDR). Two reviews evaluated the performance of commercial serological tests for the diagnosis of pulmonary TB[@ref16] and extra-pulmonary TB[@ref17], and one review evaluated the performance of noncommercial (in-house) serological tests for pulmonary TB[@ref18]. For all three reviews, studies with cross-sectional or case-control study designs were eligible for inclusion. The reference standards were culture and/or smear microscopy or, in addition, for extra-pulmonary TB, histopathological examination. The reviews of commercial serological tests for the diagnosis of pulmonary TB (68 studies)[@ref16] and extrapulmonary TB (21 studies)[@ref17] found highly variable sensitivity and specificity estimates.

For the review of non-commercial (in-house) tests for pulmonary TB, only studies evaluating tests using purified antigens were included; studies that used purified protein derivative, culture filtrates, or sonicated antigens were excluded[@ref18]. The review yielded 254 test evaluations (including 51 distinct single antigens and 30 distinct multiple-antigen combinations) and found potential candidate antigens for inclusion in a serological test in both HIV-uninfected and -infected individuals. Multiple antigens provided higher sensitivities than single antigens. However, no antigen achieved sufficient sensitivity to replace smear microscopy[@ref18].

The performance of commercially available rapid (test result available in less than 15 min) TB diagnostic tests was assessed in a laboratory-based evaluation[@ref19]. The reference standard was culture plus clinical follow-up. Serum samples were obtained from the WHO/TDR TB Bank and included specimens from Uganda, The Gambia, Canada, Tanzania, Brazil, and Spain. Test manufacturers were identified via the internet, conferences and contact with experts and TB programmes. Nineteen companies agreed to participate, seven companies declined and one withdrew. Sensitivity of the serological tests ranged from 1 to 60 per cent and specificity from 53 to 99 per cent ([Table III](#T3){ref-type="table"}). Test performance was diminished in HIV-infected individuals. An evaluation of smear plus serology yielded a gain equivalent to the detection of 57 per cent of smear negative, culture positive TB cases. However, there was a corresponding unacceptable decrease in specificity to 58 per cent[@ref19].

###### 

Performance of rapid diagnostic tests for pulmonary tuberculosis
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In order to develop policy guidance concerning commercial serological TB tests, WHO commissioned an updated systematic review[@ref20]. For this review, the reference standards were culture for pulmonary TB and culture, smear, or histopathological examination for extra-pulmonary TB. Assessment of study quality was carried out using QUADAS (Quality Assessment of Diagnostic Accuracy Studies), a validated tool to evaluate the risk of bias in diagnostic accuracy studies[@ref21]. Test performance was summarized using bivariate meta-analyses that jointly modelled sensitivity and specificity[@ref22]. The review included 14 new papers (approximately 30% of the included papers) identified since the previous reviews[@ref16][@ref17]. In total, 67 studies (5,147 participants) were included in the pulmonary TB group and 25 studies (1,809 participants) in the extra-pulmonary TB group. The results demonstrated that serological tests for both pulmonary and extra-pulmonary TB provided inconsistent and imprecise sensitivity and specificity estimates ([Table II](#T2){ref-type="table"}). Anda-TB IgG (Anda Biologicals, Strasbourg, France), the most commonly evaluated test, yielded pooled sensitivities of 76 per cent (95% CI 63, 87) in studies of smear-positive and 59 per cent (95% CI 10, 96) in studies of smear-negative patients; corresponding pooled specificities were 92 per cent (95% CI 74, 98) and 91 per cent (95% CI 79, 96), respectively[@ref20].

In the only two studies identified that evaluated HIV-infected TB patients, test sensitivities were poor. SDHO MTB test (SDHO Laboratories Inc., Canada) for pulmonary TB yielded sensitivity 16 per cent (95% CI 5, 34)[@ref23] and MycoDot (Mossman Associates, Milford) for extra-pulmonary TB yielded sensitivity 33 per cent (95% CI 19, 39)[@ref24].

The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach was used to assign a grade to the quality of evidence in the updated systematic review[@ref25]. In the GRADE system, quality of evidence reflects our confidence that an estimate of effect is correct. Quality may be compromised by five factors: risk of bias, directness of evidence, heterogeneity, precision of effect estimates, and risk of publication bias[@ref26]. The quality of studies in the updated review was graded as 'very low' based on all five factors suggesting that "the true effect is likely to be substantially different from the estimate of effect"[@ref26].

Relevance for India {#sec2-3}
===================

Dowdy and colleagues[@ref13] used a hypothetical patient cohort of 1.5 million TB suspects, a number conservatively equal to the annual volume of serological tests in India, in a decision analysis to estimate the costs and effectiveness of serological testing compared with other diagnostic tools. In this cohort, using output from the updated systematic review, serological testing for TB disease in adult Indian TB suspects was found to be more costly and even less effective than sputum smear microscopy. Specifically, the researchers found that, if used as a replacement test for sputum microscopy, serology would increase costs to the Indian TB control sector approximately 4-fold and result in 121,000 more false-positive diagnoses, 102,000 fewer disability-adjusted life years averted and 32,000 more secondary infections, despite an estimated 14,000 more TB diagnoses[@ref13].

In a root-cause analysis, Jaroslawski and Pai[@ref14] sought to understand the reasons why TB serological tests are so popular in the Indian private sector. One of the key findings in their analysis was that, given the absence of an accurate, validated, point-of-care test for TB, serological tests meet a perceived need among private providers and patients. Physicians consider smear microscopy to be insensitive and antiquated. In addition, sputum-based tests are unsuitable for the diagnosis of extra-pulmonary, smear-negative, and paediatric TB. From an economic perspective, imported molecular or liquid culture tests are too expensive, leaving serological tests as the main alternative. Although serological tests are inaccurate, various players along the value chain profit from their use, and this sustains a market for these tests. In India a large number of serological kits are available in the market. Private healthcare, in general, is poorly regulated, and doctors in the private sector do not necessarily follow standard guidelines. Reflecting upon lessons learned from serology, the authors described key characteristics for a successful new TB test: be a rapid test; be perceived by doctors as more sensitive and sophisticated than sputum smears; be suitable for the detection of extra-pulmonary TB; not require laboratories to make big investments in infrastructure/equipment; and not be too inexpensive or too expensive, but be in the middle range of approximately US \$10 (![](IJMR-135-695-g001.jpg)550)[@ref14].

Moving from evidence to recommendations {#sec2-4}
=======================================

WHO has adopted a systematic and transparent process for moving evidence to recommendations[@ref27]. In July 2010, WHO convened an Expert Group to review all available evidence on serological tests with the GRADE approach. As recommended by GRADE, the Expert Group was asked to draw conclusions based not only on the quality of evidence (considered very low), but in addition, the balance between benefits and harms, values and preferences, and estimated costs[@ref28]. After considering the evidence, the Expert Group recommended against the use of currently available serological tests.

In July 2011, WHO issued a policy stating that commercial serological tests provide inconsistent and imprecise estimates of sensitivity and specificity. There is no evidence that existing commercial serological assays improve patient-important outcomes, and high proportions of false-positive and false-negative results adversely impact patient safety. Overall data quality was graded as very low, with harms/risks far outweighing any potential benefits. It is, therefore, recommended that these tests should not be used in individuals suspected of active pulmonary or extra-pulmonary TB, irrespective of their HIV status. The WHO policy strongly encourages targeted further research to identify new/alternative point-of-care tests for TB diagnosis and/or serological tests with improved accuracy[@ref29]. Immediately following the WHO policy, the RNTCP published an advisory statement against the use of TB serological tests in India[@ref30]. More recently, an expert committee convened by the Drug Controller General of India has recommended a ban on import and sale of TB serological tests in India[@ref31] and this ban has been endorsed by the Indian health ministry.

Conclusions {#sec1-1}
===========

Findings from several systematic reviews and an independent evaluation of rapid tests suggest that serological tests for both pulmonary and extra-pulmonary TB are inaccurate. No test performs well enough to replace smear microscopy. Currently available commercial serological TB tests appear to do more harm than good because of the harm caused to patients through false-positive or false-negative tests results. Furthermore, considerable resources are required for the serological tests themselves (approx. US \$ 10/![](IJMR-135-695-g001.jpg)550/antibody or US \$ 30/![](IJMR-135-695-g001.jpg)1650 per full investigation *i.e*., three tests for specific antibody classes (IgG, IgM and IgA).

Echoing these concerns, in a recent editorial Singh and Katoch wrote, 'Unfortunately, unethical medical practices provided major boost to these kits in recent years, without bothering much on quality of tests and implications of false-positive and false negative results.... This editorial is not the obituary for serology. Immunological detection with appropriate sensitivity and specificity will remain an attractive research option for developing immunodiagnosis of tuberculosis"[@ref32].

Serological tests: The way forward {#sec2-5}
----------------------------------

Despite the impressive scale-up of the DOTS programme by the RNTCP, India continues to report more than two million TB cases every year and undiagnosed and mismanaged TB is partly responsible for this[@ref33]. Recognizing these challenges, the Government of India has set an ambitious goal of providing universal access to quality diagnosis and treatment for all TB patients in the country (National Strategic Plan, 2012-2017). To improve TB diagnosis in India, several efforts are needed in parallel. India recently made TB a notifiable disease to ensure all cases in the private sector are reported to RNTCP. India must adopt new tools that are accurate, validated and WHO-endorsed, and replace suboptimal tests with good tests that can impact patient outcomes and reduce TB transmission in the community. Innovative tools and innovative delivery systems that engage both public and private sectors are essential for reaching this goal. Recently, the Indian Academy of Pediatrics discouraged the use of serological tests[@ref34], and other medical associations like the Indian Association of Medical Microbiologists, Indian Chest Society, and Indian Medical Association must follow suit. The Drug Controller General of India must tighten regulation of all *in vitro* diagnostics in the country and ensure that diagnostic tests undergo through validation before approval. India\'s RNTCP must set clear specifications for all TB diagnostics used in the country. Furthermore, increased attention must be paid to quality assurance in laboratories in India. Greater engagement of the private sector is also needed to reduce the misdiagnosis of TB and to replace bad tools with newer validated technologies.
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